Omeprazole Teva Uk

Omeprazole, the active ingredient in Omeprazole Teva Uk, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid production and is used to treat conditions such as gastro‑esophageal reflux disease, peptic ulcer disease, and Zollinger‑Ellison syndrome. GNH USA supplies Omeprazole Teva Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole is a proton pump inhibitor that lowers gastric acidity in several acid‑related disorders.

- Gastro‑esophageal reflux disease (GERD): alleviates heartburn and promotes healing of esophageal irritation. - Peptic ulcer disease: supports ulcer healing by reducing acid exposure. - Helicobacter pylori eradication therapy: used in combination regimens to improve bacterial eradication rates. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion in this rare endocrine disorder.

Omeprazole may cause a range of adverse reactions.

Common Side Effects: - Headache - Diarrhea - Abdominal pain - Nausea - Flatulence - Constipation

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis, angioedema) - Clostridioides difficile‑associated colitis - Elevated liver enzymes or hepatitis - Hypomagnesemia leading to muscle cramps or arrhythmia - Increased risk of bone fractures with long‑term use - Severe skin reactions such as Stevens‑Johnson syndrome.

Before initiating therapy, consider the following precautions: - Assess renal and hepatic function: dose adjustment may be needed in impairment. - Use cautiously in elderly patients: increased susceptibility to fractures. - Avoid abrupt discontinuation after long‑term use: taper to prevent rebound acid hypersecretion. - Monitor serum magnesium levels during prolonged therapy. - Use the lowest effective dose for the shortest duration required. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Atazanavir and other protease inhibitors: reduced antiviral efficacy. - Nelfinavir: decreased plasma concentrations. - Rilpivirine: diminished antiretroviral activity. - Clopidogrel: impaired conversion to active metabolite, reducing antiplatelet effect. - Methotrexate: increased toxicity due to reduced clearance.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR, requiring closer monitoring. - Digoxin: increased serum levels, risk of toxicity. - Phenytoin and carbamazepine: reduced anticonvulsant concentrations. - Ketoconazole and other azole antifungals: decreased absorption. - Certain HIV medications (e.g., efavirenz): altered plasma levels.